|
Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU. |
| |
|
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer |
| |
|
|
Research Funding - Novartis |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Novartis (Inst) |
| |
|
Research Funding - Novartis (Inst) |
| |
|
Research Funding - Novartis (Inst) |
| |
|
|
Research Funding - Novartis |
| |
|
Honoraria - Bristol-Myers Squibb; Novartis; Roche/Genentech |
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Merck |
Research Funding - AstraZeneca/MedImmune; GlaxoSmithKline; Roche/Genentech |